<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-85D7AGV3</identifier><date>2009</date><creator>Sonc, Monika</creator><relation>documents/doc/8/URN_NBN_SI_doc-85D7AGV3_001.pdf</relation><relation>documents/doc/8/URN_NBN_SI_doc-85D7AGV3_001.txt</relation><format format_type="volume">13</format><format format_type="issue">2</format><format format_type="type">article</format><format format_type="extent">str. 124-125</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID">855163</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-85D7AGV3</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">Administration and dosage</subject><subject language_type_id="eng">Antineoplastic agents</subject><subject language_type_id="slv">Antineoplastiki</subject><subject language_type_id="eng">drug</subject><subject language_type_id="eng">Drug stability</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">Predpisovanje in doziranje</subject><subject language_type_id="slv">stabilnost</subject><subject language_type_id="slv">zdravila</subject><subject language_type_id="slv">Zdravilo, stabilnost</subject><title>Informacije o stabilnosti onkoloških zdravil</title><title>vloga bolnišničnega farmacevta</title></Record>